188 related articles for article (PubMed ID: 30666913)
1. Evaluation of Serum Calprotectin Level and Disease Activity in Patients with Rheumatoid Arthritis.
Aghdashi MA; Seyedmardani S; Ghasemi S; Khodamoradi Z
Curr Rheumatol Rev; 2019; 15(4):316-320. PubMed ID: 30666913
[TBL] [Abstract][Full Text] [Related]
2. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
[TBL] [Abstract][Full Text] [Related]
3. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.
Hurnakova J; Hulejova H; Zavada J; Hanova P; Komarc M; Mann H; Klein M; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
PLoS One; 2017; 12(8):e0183420. PubMed ID: 28832684
[TBL] [Abstract][Full Text] [Related]
4. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.
Inciarte-Mundo J; Ruiz-Esquide V; Hernández MV; Cañete JD; Cabrera-Villalba SR; Ramirez J; Yagüe J; Sanmarti R
Rheumatology (Oxford); 2015 Dec; 54(12):2239-43. PubMed ID: 26242859
[TBL] [Abstract][Full Text] [Related]
5. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.
Hurnakova J; Zavada J; Hanova P; Hulejova H; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Komarc M; Vencovsky J; Pavelka K; Senolt L
Arthritis Res Ther; 2015 Sep; 17(1):252. PubMed ID: 26373925
[TBL] [Abstract][Full Text] [Related]
6. Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.
García-Arias M; Pascual-Salcedo D; Ramiro S; Ueberschlag ME; Jermann TM; Cara C; Martín-Mola E; Balsa A
Mol Diagn Ther; 2013 Feb; 17(1):49-56. PubMed ID: 23329363
[TBL] [Abstract][Full Text] [Related]
7. Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.
Hurnakova J; Hulejova H; Zavada J; Komarc M; Cerezo LA; Mann H; Vencovsky J; Pavelka K; Senolt L
Clin Rheumatol; 2018 Aug; 37(8):2055-2062. PubMed ID: 29656372
[TBL] [Abstract][Full Text] [Related]
8. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission.
Hurnakova J; Hulejova H; Zavada J; Komarc M; Hanova P; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
PLoS One; 2016; 11(11):e0165498. PubMed ID: 27832086
[TBL] [Abstract][Full Text] [Related]
9. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.
Hammer HB; Odegard S; Fagerhol MK; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
Ann Rheum Dis; 2007 Aug; 66(8):1093-7. PubMed ID: 17234650
[TBL] [Abstract][Full Text] [Related]
10. Calprotectin levels in patients with rheumatoid arthritis to assess and association with exercise treatment.
Acar A; Guzel S; Sarifakioglu B; Guzel EC; Guzelant AY; Karadag C; Kiziler L
Clin Rheumatol; 2016 Nov; 35(11):2685-2692. PubMed ID: 27094943
[TBL] [Abstract][Full Text] [Related]
11. Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study.
Sakellariou G; Lombardi G; Vitolo B; Gomarasca M; Faraldi M; Caporali R; Banfi G; Montecucco C
Clin Exp Rheumatol; 2019; 37(3):429-436. PubMed ID: 30299248
[TBL] [Abstract][Full Text] [Related]
12. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
[TBL] [Abstract][Full Text] [Related]
13. Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.
Jarlborg M; Courvoisier DS; Lamacchia C; Martinez Prat L; Mahler M; Bentow C; Finckh A; Gabay C; Nissen MJ;
Arthritis Res Ther; 2020 May; 22(1):105. PubMed ID: 32375861
[TBL] [Abstract][Full Text] [Related]
14. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
15. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
16. Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis.
Bae SC; Lee YH
Postgrad Med; 2017 Jun; 129(5):531-537. PubMed ID: 28425837
[TBL] [Abstract][Full Text] [Related]
17. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis.
Hammer HB; Haavardsholm EA; Kvien TK
Scand J Rheumatol; 2008; 37(3):179-82. PubMed ID: 18465451
[TBL] [Abstract][Full Text] [Related]
18. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis.
Hammer HB; Ødegård S; Syversen SW; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
Ann Rheum Dis; 2010 Jan; 69(1):150-4. PubMed ID: 19095696
[TBL] [Abstract][Full Text] [Related]
19. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
Jonsson MK; Sundlisæter NP; Nordal HH; Hammer HB; Aga AB; Olsen IC; Brokstad KA; van der Heijde D; Kvien TK; Fevang BS; Lillegraven S; Haavardsholm EA
Ann Rheum Dis; 2017 Dec; 76(12):2031-2037. PubMed ID: 28814431
[TBL] [Abstract][Full Text] [Related]
20. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
